Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VBIT-4 is a small molecule inhibitor of Voltage-Dependent Anion Channel 1 (VDAC1) oligomerization. VDAC1 is a key protein in the outer mitochondrial membrane that regulates the flux of ions and metabolites; its oligomerization is associated with mitochondrial membrane permeabilization and the release of pro-apoptotic factors. While VBIT-4 has demonstrated cytoprotective effects in various disease models (such as diabetes and neurodegeneration) by preventing VDAC1-mediated apoptosis, recent research indicates that its effects may be context-dependent. Specifically, in models of doxorubicin-induced cardiomyopathy, VBIT-4 has been shown to exacerbate mitochondrial dysfunction by increasing mitochondrial iron accumulation and oxidative stress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VBIT-4.